Detection Of Serum Tumor Markers Research Articles

Diagnostic value of joint detection of serum tumor markers in different pathological types of lung cancer

Diagnostic value of joint detection of serum tumor markers in different pathological types of lung cancer

Assessment of the Diagnostic and Prognostic Efficacy of Combined Detection of Serum Tumor Markers in Patients with Lung Cancer

Assessment of the Diagnostic and Prognostic Efficacy of Combined Detection of Serum Tumor Markers in Patients with Lung Cancer

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs), which has attracted much attention in the treatment of ALK-positive non-small cell lung cancer (NSCLC). At present, there are few reports on the efficacy and safety of alectinib in Chinese population. Moreover, biomarkers reflecting prognosis and efficacy are exceedingly needed. This study assessed the efficacy of alectinib in patients with ALK-positive NSCLC and analyzed the prognostic factors. Patients with ALK-positive NSCLC who were confirmed by histopathology or cytology at the Affiliated Cancer Hospital of Nanjing Medical University between October 2018 and October 2021 were enrolled. All patients were treated with alectinib. The clinical characteristics and circulating tumor biomarkers before and after treatment were collected. Kaplan-Meier test was used to calculate the progression-free survival (PFS). Univariate and multivariate Cox regression analyses were used to explore the influencing factors on PFS. Incidence of adverse events was observed. Twenty patients progressed after first-line treatment (n=59) with alectinib, and 21 patients progressed following second-line treatment (n=36) with alectinib. The median PFS of first-line treatment patients was not achieved, and the median PFS of patients undergoing second-line treatment was 15.0 months [95% confidence interval (CI): 0.00-32.23]. The most common adverse reactions were liver dysfunction (37.50%), anemia (37.50%), and constipation (20.83%). The incidence of grade III and above adverse reactions was 6.25%. Univariate analysis showed that neutrophil-to-lymphocyte ratio [NLR; hazard ratio (HR) =0.424, P=0.005] carcinoembryonic antigen (CEA; HR =0.482, P=0.029), lactate dehydrogenase (LDH; HR =0.327, P<0.001), carbohydrate antigen (CA)199 (HR =0.313, P=0.002), and circulating cell free DNA (cfDNA; HR =0.229, P=0.008) concentration levels were associated with PFS, and multivariate analysis showed that NLR (HR =3.058, P=0.034) was independent prognostic factor. After three months of treatment, CEA, CA199, NLR, and LDH, could further predict the prognosis of alectinib treatment. The efficacy and safety of alectinib as a first-line or second-line treatment for ALK-positive NSCLC in keeping with published prospective studies. CEA, CA199, NLR, and LDH within the normal range after three months of treatment were associated with good prognosis. Detection of serum tumor markers can indicate therapeutic success in patients treated with alectinib.

The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer.

Simple SummaryThis study recruited 3272 non-small cell lung cancer (NSCLC) cases to analyze the predictive abilities of serum tumor markers (CEA, SCC-Ag, CYFRA 21-1, NSE, ProGRP, TPSA and CA199) for metastasis and clinical stage, and found that tumor marker levels may be indicative of tumor metastasis (intrapulmonary, lymphatic and distant metastasis) and stage. Increased CEA and CA199 provided an accurate prediction of intrapulmonary and distant metastasis. Increased CEA, CYFRA 21-1 and CA199 provided an accurate prediction of lymphatic metastasis and higher tumor stage. Combined detection of serum tumor markers can indicate tumor metastasis and stage in NSCLC patients.Objective: This study aimed to explore the roles of serum tumor markers for metastasis and stage of non-small cell lung cancer (NSCLC). Methods: This study recruited 3272 NSCLC patients admitted to the Tianjin Union Medical Center and the Tianjin Medical University Cancer Institute and Hospital. The predictive abilities of some serum tumor markers (carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), cytokeratin-19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP), total prostate-specific antigen (TPSA) and carbohydrate antigen 199 (CA199)) for NSCLC metastasis (intrapulmonary, lymphatic and distant metastasis) and clinical stage were analyzed. Results: Tumor markers exhibited different numerical and proportional distributions in NSCLC patients. Elevated CEA, CYFRA 21-1 and CA199 levels were indicative of tumor metastasis and stage. Increased CEA and CA199 provided an accurate prediction of intrapulmonary and distant metastasis with the area under the receiver operator characteristic curve (AUC) of 0.69 both (p < 0.001); Increased CEA, CYFRA 21-1 and CA199 provided an accurate prediction of lymphatic metastasis with the AUC of 0.62 (p < 0.001). Conclusion: Combined detection of serum tumor markers can indicate tumor metastasis and stage in NSCLC patients.

Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer.

This study aimed to investigate the value of combining the detection of serum tumor markers, namely, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, CA 242, and CA 50, with fecal occult blood (FOB) testing in the diagnosis of colorectal cancer (CRC). One hundred patients with CRC who were diagnosed and treated at the First Hospital of Jiaxing, Zhejiang Province, China, between January 2019 and April 2020 were enrolled as the case group, and 200 healthy people who underwent a physical examination at the hospital during the same period were recruited as the control group. The concentrations of CEA, CA199, CA242, and CA50 in serum were measured alongside FOB indicators. Compared with the control group, the concentrations of CEA, CA199, CA242, and CA50 in the case group were significantly higher, and they were related to age, tumor differentiation, tumor stage, and other clinicopathological features (P<0.05). The diagnostic performance of the combination of four tumor markers for CRC was significantly better than when using a single marker (four-combined test: AUC (area under the curve) AUC=0.80), and the diagnostic performance was further improved after adding the fecal occult blood test test (FOBT) results (five-combined test: AUC=0.90). The combined detection of the five indexes was found to be effective for the early diagnosis of CRC (AUC=0.87). We concluded that the detection of serum tumor markers CEA, CA199, CA242, and CA50 combined with an FOBT could significantly improve the sensitivity and accuracy of a CRC diagnosis and contributed to an early diagnosis and appropriate treatment.

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer.

The objective of this study was to analyze the value of artificial intelligence algorithm-based computerized tomography (CT) image combined with serum tumor markers for diagnoses of pancreatic cancer. In the study, 68 hospitalized patients with pancreatic cancer were selected as the experimental group, and 68 hospitalized patients with chronic pancreatitis were selected as the control group, all underwent CT imaging. An image segmentation algorithm on account of two-dimensional (2D)-three-dimensional (3D) convolution neural network (CNN) was proposed. It also introduced full convolutional network (FCN) and UNet network algorithm. The diagnostic performance of CT, serum carbohydrate antigen-50 (CA-50), serum carbohydrate antigen-199 (CA-199), serum carbohydrate antigen-242 (CA-242), combined detection of tumor markers, and CT-combined tumor marker testing (CT-STUM) for pancreatic cancer were compared and analyzed. The results showed that the average Dice coefficient of 2D-3D training was 84.27%, which was higher than that of 2D and 3D CNNs. During the test, the maximum and average Dice coefficient of the 2D-3D CNN algorithm was 90.75% and 84.32%, respectively, which were higher than the other two algorithms, and the differences were statistically significant (P < 0.05). The penetration ratio of pancreatic duct in the experimental group was lower than that in the control group, the rest were higher than that in the control group, and the differences were statistically significant (P < 0.05). CA-50, CA-199, and CA-242 in the experimental group were 141.72 U/mL, 1548.24 U/mL, and 83.65 U/mL, respectively, which were higher than those in the control group, and the differences were statistically significant (P < 0.05). The sensitivity, specificity, positive predictive value, and authenticity of combined detection of serum tumor markers were higher than those of CA-50, CA-199, and CA-242, and the differences were statistically significant (P < 0.05). The results showed that the proposed algorithm 2D-3D CNN had good stability and image segmentation performance. CT-STUM had high sensitivity and specificity in diagnoses of pancreatic cancer.

SERS Immunosensor Based on High-Density “Hotspots” Au@SiO2 Array Substrate and Au-Ag Nanoshells Probes for Ultrasensitive Detection of Dual Biomarkers in the Cervical Cancer Serum

Cervical cancer is a common cause of cancer-related death in women worldwide, and quantitative detection of serum tumor markers has practical implications for diagnosing cervical cancer. In this study, a novel surface-enhanced Raman scattering (SERS)-based immunosensor for the hypersensitive simultaneous detection of survivin and osteopontin (OPN) in cervical cancer serum was proposed, which was composed of the AuNPs@SiO2 microspheres (Au@SiO2) array immunosubstrate and Au-Ag nanoshells (Au-AgNSs) immunoprobes. The experimental results demonstrated that the constructed SERS immunosensor exhibited satisfactory selectivity and reproducibility while possessing detection limits as low as 0.908[Formula: see text]pg/mL and 0.813[Formula: see text]pg/mL for survivin and OPN in human serum. Finally, its usefulness in real serum samples (from healthy subjects, cervical intraepithelial neoplasia 1 (CIN 1), CIN 2, CIN 3 and cervical cancer patients) was verified, and the detection data were in good agreement with the enzyme-linked immunosorbent assay results. This immunosensor has excellent performance, which is promising for the early screening of cancer.

Application Value of Combined Detection of DCE-MRI and Serum Tumor Markers HE4, Ki67, and HK10 in the Diagnosis of Ovarian Cancer.

Objective To investigate the application value of the combined detection of DCE-MRI and serum tumor markers (HE4, Ki67, and HK10) in the diagnosis of ovarian cancer. Methods The clinical data of 40 patients with advanced ovarian cancer (AOC) confirmed by surgery and pathology in our hospital from February 2019 to February 2020 were retrospectively analyzed. All patients received DCE-MRI, the detection of serum tumor markers HE4, Ki67, and HK10, and the combined detection of DCE-MRI and the serum tumor markers (HE4, Ki67, and HK10). The application value of the three detection methods was analyzed. Results The number of true positives in the single detection (DCE-MRI detection and the detection of serum HE4, Ki67, and HK10) was notably lower than that in the combined detection. The sensitivity, specificity, and accuracy of the single detection were notably lower compared with the combined detection. The area under the curve in the ROC of the combined detection was notably larger than that of the single detection. The results of the combined detection were better than those of the single detection (P < 0.05), with the highest sensitivity of the combined detection. Conclusion The combined detection of DCE-MRI and the serum tumor markers (HE4, Ki67, and HK10) can effectively improve the diagnostic accuracy of AOC patients, with high sensitivity and specificity, which has an important diagnostic value in clinic.

Value of combined detection of serum tumor markers and M2-PK in colorectal cancer screening

Value of combined detection of serum tumor markers and M2-PK in colorectal cancer screening

The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.

To explore the clinical value of combined detection of serum tumor markers in lung cancer, including carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), cytokeratin 19 fragment (CYFRA 21-1), neuron specific enolase (NSE), and squamous carcinoma antigen (SCCA). The expression levels were compared among groups, and the combined effects of these tumor markers in the diagnosis of lung cancer were analyzed. In addition, EGFR gene mutations were detected in some patients with NSCLC. There were 776 patients (age 59.78 ± 10.39 years) with lung cancer and 794 controls (age 58.26 ± 15.73 years) included in our study. In this study, tumor markers were detected in lung cancer patients and controls. Individual sensitivity of the tumor markers sorted in descending order were CEA > CYFRA21-1 > CA15-3 > NSE, and the specificities were NSE > CYFRA21-1 > CEA > CA15-3. The combination of CEA + CA15-3 + CYFRA21-1 + NSE ranked the highest in the sensitivity index (75.00%) and specificity index (98.61%) in lung cancer. In adenocarcinoma, the area under the ROC curve (AUROC) of CEA (0.665) and CYFRA21-1 (0.631) were higher than those of CA15-3 (0.559) and NSE (0.507). In squamous carcinoma, the AUC of CYFRA21-1 (0.722) and SCC (0.628) were higher than those of CEA (0.579), CA15-3 (0.524), and NSE (0.552). In small cell carcinoma, the AUC of NSE (0.654) was higher than those of CEA (0.616), CYFRA21-1 (0.555), and CA15-3 (0.482). These serum tumor markers are valuable indicators in the clinical use. The combination of tumor markers can be used as a method to improve the effectiveness of clinical diagnosis for lung cancer.

Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.

Pancreatic cancer occupies the fourth place as a cause of death from cancer, and the mortality rate is similar to the number of newly detected cases. Due to the late diagnosis, only 5-6% of patients with pancreatic cancer survive for five years. Given that early diagnosis is critical for improving patients’ survival rates, there is an urgent need for the discovery and validation of new biomarkers with sufficient sensitivity and specificity to help diagnose pancreatic cancer early. Detection of serum tumor markers (CA19-9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer. The combination of miR-16, miR-196a and CA19-9 plasma level was more effective, especially in early tumor screening. Furthermore, recent studies reported that mainly miR-21, miR-155 and miR-196 were dysregulated in IPMN (intraductal papillary mucinous neoplasms) and PanIN (pancreatic intraepithelial neoplasia) lesions, suggesting their usefulness as early biomarkers of these diseases. The reduced rate of apoptosis plays a crucial role in carcinogenesis, and it is one of the most important characteristics acquired by pancreatic cancer cells, which protects them from attack by the immune system and reduces the effectiveness of pharmacological treatment. This review summarizes the data concerning the clinical utility of selected biomarkers in pancreatic cancer patients. The review mainly focuses on the genetic aspects of signaling pathway disorders associated with apoptosis in the pathogenesis and diagnosis of pancreatic cancer.

Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.

To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis of pancreatic cancer cases treated with concurrent chemotherapy. 52 patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. The electrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, and a CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier method was used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazard model was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival time of patients with pancreatic cancer. The levels of serum CA19-9, CEA, CA125 and CA242 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases and healthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125 and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity and specificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviously higher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of 52 patients with pancreatic cancer was 10 months (95% CI7.389~12.611).. Patients with the increasing level of serum CA19-9, CEA, CA125, CA242 had shorter survival times (P=0.047. 0.043, 0.0041, 0.029). COX regression analysis showed that CA19-9 was an independent prognostic factor for patients with pancreatic cancer (P=0.001, 95%CI 2.591~38.243). The detection of serum tumor markers (CA19.9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer and joint detection of tumor markers helps improve the diagnostic efficiency. Moreover, CA19-9 is an independent prognostic factor for patients with pancreatic cancer.

Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer

To explore the predictive value of tumor markers, including cancer antigen 72-4 (CA72-4), cancer antigen 15-3 (CA15-3) and cancer antigen 125 (CA125), in single or combined detection, for the diagnosis of ovarian cancer. 120 patients diagnosed with ovarian cancer from August 2011 to March 2013 and 80 patients diagnosed with benign ovarian tumors were enrolled in this test, along with 50 health examination women randomly selected from the database as controls. Serum levels of CA72-4, CA15-3 and CA125 in this study were determined by electrochemiluminescence (ECL). Serum levels of CA72-4, CA15-3 and CA125 in ovarian cancer were higher than those in healthy group and benign group (P<0.01).The sensitivity of combined detection of those three tumor markers for diagnosis of ovarian cancer was obviously higher than with single detection with each marker (P<0.01). CA72-4, CA15-3 and CA125 could be a good combination in the diagnosis of ovarian cancer. Patients whose tumor markers continue to increase should be highly suspected of malignancy.

Diagnostic value of combined detection of serum tumor markers for lung cancer

Objective To investigate the diagnostic value of combined detection of serum tumor markers,including CEA,CA125,neuron-specific enolase (NSE) and cytokeratin fragment antigen 21-1 (CYFRA21-1) for lung cancer patients.Methods The subjects involved 138 diagnosed lung cancer patients (82 males,56 females,average age 58.6 years,from October 2010 to March 2012),96 patients with benign lung diseases (56 males,40 females,average age 51.3 years) and 45 healthy adults (30 males,15females,average age 43.9 years).The pathological types of lung cancer consisted of 66 squamous cell carcinoma (SCC),52 adenocarcinoma and 20 small cell lung cancer (SCLC).The serum levels of CEA,CA125,NSE and CYFRA21-1 were measured with electrochemiluminescence immunoassay.The diagnostic efficacy for different pathological types was compared among each single tumor marker and combination of tumor markers.One-way analysis of variance q test were used for statistical analysis.Results The serum levels of CEA,CA125,NSE and CYFRA21-1 in patients with lung cancer were higher than those in patients with benign lung diseases and in healthy subjects (CEA:(19.99±30.99),(10.78±19.77),(3.25±3.42) μg/L;CA125:(79.70±95.98),(44.96±44.97),(20.66±7.13) μg/L; NSE:(35.23±40.22),(15.31±8.42),(13.30±5.65) μg/L; CYFRA21-1:(18.07±43.71),(8.30±8.83),(3.13±1.60) μg/L; F=4.481,5.436,4.776,6.002,all P＜0.05).The highest level of CEA,NSE or CYFRA21-1 were found in adenocarcinoma (F=4.932,P＜0.05),SCLC (F=5.119,P＜0.05) or SCC (F=5.378,P＜0.05),respectively.The highest sensitivity tumor markers for SCC,SCLC and adenocarcinoma were CYFRA21-1 (78.8％,52/66),NSE (75.0％,15/20) and CEA (57.7％,30/52),respectively.In combined detection,the highest sensitivity combinations for SCC,SCLC and adenocarcinoma were CEA+CYFRA21-1+NSE (89.4％,59/66),CEA+CYFRA21-1+NSE (80.0％,16/20) and CEA+CA125+NSE (78.8％,41/52),respectively.Conclusions Combined detection of serum tumor markers is more sensitive for the diagnosis of lung cancer.The expressions of the above four tumor markers is correlated with pathological types of lung cancer. Key words: Lung neoplasms ; Carcinoembryonic antigen ; Antigens, tumor-associated,carbohydrate ; Phosphopyruvate hydratase ; Keratins

Clinical application of combined detection of serum tumor markers in diagnosis of lung cancer

Objective To investigate the significance of combined detection of serum tumor markers in the diagnosis of lung cancer,and to select the most sensitive serum tumor markers.Methods Enzyme-linked immunosorbent assay was used to detect the serum tumor markers of 62 lung cancer patients and 62 healthy persons,who were neuron specific enolase enzyme (NES),carbohydrate antigen 125 (CA 125),cytokeratin 19 (CYFRA21-1) and carcinoembryonic antigen(CEA).Results The level of serum CEA,CA125,CYFRA21-1,and NES of the lung cancer group were all higher than those of the control group (all P ＜ 0.05).Among the four kinds of tumor markers,CA125 had the highest sensitivity(59.7％),which was followed by CEA(53.2％).The sensitivity of the four kinds of joint detection was 87.1％,the highest sensitivity of three markers joint detection was CEA + CA125 + CYFRA21-1 (87.1％),while that of the two kinds of joint detection was CEA + CA125 (75.8％).Conclusion There are high clinical significance in the diagnosis of lung cancer with four kinds of serum tumor markers,CEA + CA125 + CYFRA21-1 can be used as the best markers for joint detection of lung cancer with high sensitivity. Key words: Lung neoplasms; Diagnosis

Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer

The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden's index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.

Detection of serum tumor markers in multiple myeloma using the CLINPROT system

The discovery of biomarkers unique to multiple myeloma (MM) is of great importance to clinical practice. This study was designed to identify serum tumor marker candidates of MM in the mass range of 700-10000 Da. Serum samples from 48 MM patients and 74 healthy controls were collected and classified into a training dataset (MM/controls: 26/26) and a testing dataset (MM/controls: 22/48). Weak cation exchange magnetic beads, MALDI-TOF MS and analytic software in the CLINPROT system were used to do serum sample pre-fractionation, data acquisition and data analysis. Peak statistics were performed using Welch's t test. Mass spectra from the two model generation cohorts in the training dataset were analyzed by the Supervised Neural Network Algorithm (SNNA) in ClinProTools((TM)) to identify the mass peaks with the highest separation power. The resulting diagnostic model was subsequently validated in the testing dataset. A total of 89 discriminating mass peaks were detected by ClinProTools((TM)) in the range of 700-10000 Da using a signal to noise threshold of 3.0. Of these, 49 peaks had statistical significance (P < 0.0001) and four peaks with the highest separation power were picked up by SNNA to form a diagnostic model. This model achieved high sensitivity (86.36 %) and specificity (87.5 %) in the validation in the testing dataset. Using CLINPROT system and MB-WCX we found four novel biomarker candidates. The diagnostic model built by the four peaks achieved high sensitivity and specificity in validation. CLINPROT system is a powerful and reliable tool for clinical proteomic research.

Meta-analysis of serum tumor markers in lung cancer

背景与目的血清肿瘤标志物的检测对肺癌的早期诊断有着重要的意义。本研究旨在通过回顾性统计分析，总结肺癌血清肿瘤标志物检测的临床意义及特点。方法应用meta分析方法对有关肺癌血清肿瘤标志物的文献进行综合定量评价。入选712篇文献，病例组、对照组病例均 > 20例，共统计肿瘤血清52 832例，对照血清32 037例。结果13项肿瘤标志物对肺癌具有诊断意义，CEA、CA125、CYFRA21-1、TPA、SCCAg、DKK1、NSE和ProGRP的敏感度分别为47.50%、50.11%、57.00%、50.93%、49.00%、69.50%、39.73%和51.48%，特异度分别为92.34%、80.19%、90.16%、88.41%、91.07%、92.20%、89.11%和94.89%。多指标联合分析显示，NSE+ProGRP对小细胞肺癌的诊断敏感度和特异度分别为88.90%和72.82%。SCCAg+CYFRA21-1联合肿瘤生长因子TSGF对鳞癌诊断的敏感度和特异度分别为95.30%和74.20%；CA153+Ferrtin+CEA对肺癌诊断的敏感度和特异度分别为91.90%和44.00%。结论肿瘤血清标志物对早期肺癌的诊断有临床意义，单项指标检测敏感度及特异度较低，多指标联合检测能提高诊断的敏感度和特异度。

Rational use of clinical detection of serum tumor markers in diagnosis of colorectal cancer

结直肠癌是位居世界第三的恶性肿瘤,在我国其发病率居胃肠道肿瘤的第二位,平均5年生存率不超过40%.目前,结直肠癌的诊断主要依据结肠镜及病理检查,但由于各种原因限制,尚不能作为普查方法.肿瘤标志物检测具有方便、快捷等优点,在结直肠癌筛选、诊断、预后判断等方面越来越受到关注.迄今,较广泛用于临床的是肿瘤标志物的血清检测,主要有癌胚抗原(CEA)等的蛋白类抗原,CA242等的糖链抗原及转化生长因子-β等激素类.蛋白芯片技术具有高通量、快速方便及所需样本少的优点,是一种较好的大肠癌辅助诊断手段,近年来的一些研究表明,多种肿瘤标志物蛋白芯片联合检测可提高结直肠癌诊断的敏感性和特异性,有较好的临床应用前景。